- Home
- RMCF vs LSTA Comparison
RMCF vs LSTA Comparison
Compare RMCF & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | LSTA |
|---|---|---|
| Founded | 1981 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 16.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | LSTA |
|---|---|---|
| Price | $2.40 | $4.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 77.9K | ★ 365.7K |
| Earning Date | 01-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,638,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $1.12 | $1.81 |
| 52 Week High | $2.60 | $4.89 |
Technical Indicators
Market Signals| Indicator | RMCF | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 68.70 | 86.51 |
| Support Level | $2.21 | $4.55 |
| Resistance Level | $2.60 | $4.72 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 81.91 | 89.07 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.